EMA regulatory approval changes for biosimilars on the horizon in the E.U.?
Biosimilars, biosimilarity—what does ‘highly similar’ mean?
Why are generic drugs the ‘same’ and biosimilars only ‘similar’ to their corresponding reference products?
Global Dis-Harmonization of Biosimilar Naming and Labeling
Subscribe: Subscribe via RSS
Firm/Org